Cargando…
Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Autores principales: | Nie, Tina, Blair, Hannah A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653353/ https://www.ncbi.nlm.nih.gov/pubmed/36190651 http://dx.doi.org/10.1007/s40263-022-00957-7 |
Ejemplares similares
-
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022) -
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
por: Marignier, Romain, et al.
Publicado: (2021) -
Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders
por: Yan, Li, et al.
Publicado: (2022) -
Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis
por: Yan, Li, et al.
Publicado: (2021) -
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Frampton, James E.
Publicado: (2020)